Product sourcing before a med spa sale: repair the evidence and the process

Before selling a med spa, verify product suppliers, preserve purchase and inventory records, and have qualified reviewers investigate unexplained or questionable sourcing. Separate current process improvements from historical exposure. Recalculate earnings using supportable product costs, document remediation truthfully, and disclose material findings through counsel. A new purchasing policy does not erase what happened before it.

Why should sourcing be reviewed before buyers ask?

Product purchasing affects patient safety, earnings, inventory value, and the credibility of the seller’s records. A buyer who sees unusually low costs will want to know why. The answer could be legitimate purchasing terms, a timing issue, incomplete accounting, or a serious sourcing concern requiring investigation.

FDA’s counterfeit Botox alert describes patient risks associated with products obtained from unlicensed sources. The sale team should not treat packaging familiarity or historical use without an obvious complaint as proof that purchasing was appropriate. Qualified reviewers need the actual supplier and product evidence.

Sourcing remediation is the documented work to identify and address weaknesses in purchasing, product records, and related controls. It does not certify that every historical product was legitimate or eliminate possible legal or clinical consequences. Define what was reviewed, what changed, and what remains unresolved.

Which evidence should you preserve first?

Collect supplier names and accounts, purchase invoices, payment records, product descriptions, relevant lot and expiration information, shipping records where available, inventory logs, credits, returns, and rebates. Retain the original files and dates. Keep a record of who assembled the materials and which periods are incomplete.

Do not reconstruct an invoice or alter a product log to make the file appear complete. If an entry is corrected, preserve the original and document the basis. A truthful gap is a problem that can be assessed; a fabricated record creates a different and potentially more serious problem.

Keep clinical or patient-linked information in the appropriately controlled review environment. The commercial team may need a status summary rather than unrestricted underlying records. Counsel and qualified clinical reviewers should determine what is necessary for investigation, response, and transaction disclosure.

How do you verify suppliers without relying on marketing claims?

FDA’s Know Your Source guidance urges healthcare professionals to verify supplier licensing and understand prescription-drug sources. Follow the applicable verification process with qualified personnel. A professional-looking website, discount offer, or familiar sales representative does not replace evidence of the supplier’s authorized status.

Document verification date, source, reviewer, account entity, and any discrepancy. Compare the supplier on the invoice with the party receiving payment and the party shipping goods. A mismatch may have an explanation, but it should be resolved rather than ignored because purchases are inexpensive.

Different products can have different distribution and regulatory requirements. Have the responsible professionals assess what evidence is needed for the products actually used. Do not apply a single checklist as if prescription drugs, medical devices, skincare retail, and compounded preparations are interchangeable categories.

How should you reconcile purchasing to inventory and use?

Begin with opening inventory, add purchases and transfers, subtract documented usage, waste, returns, and other supported movements, then compare with closing inventory. Use consistent units and identify conversion methods. Avoid equating a vial, unit, syringe, package, and completed treatment without an appropriate reconciliation.

These invented figures demonstrate reconciliation only and are not dosing or handling instructions. Investigate differences with the accountant and responsible clinical personnel. Timing, transfers, system definitions, and missing entries can matter. An unexplained variance is a question to resolve, not automatically proof of diversion or counterfeiting.

What should happen when a questionable product is identified?

Escalate promptly to qualified clinical and legal advisors. They should assess patient safety, product handling, manufacturer or supplier verification, reporting, notification, insurance, and any required response. The transaction timetable should not control clinical decisions or delay an appropriate safety response.

Preserve relevant evidence and a factual chronology. Do not continue presenting disputed inventory as ordinary saleable stock while review remains unresolved. The responsible professionals should determine what can be used, held, returned, or otherwise handled under applicable requirements.

FDA guidance on dermal fillers describes product-specific approved uses and risks. It reinforces the need to assess the actual product and service rather than assume all injectables have the same status. This guide organizes transaction preparation; it does not authenticate products or prescribe a clinical remediation protocol.

How can sourcing findings change the earnings story?

Recalculate product costs using supported accounting and a lawful purchasing model. A historical margin based on an unverified source may not be transferable. Separate a cost correction from anticipated buyer purchasing savings and from one-time remediation expense.

For illustration, suppose recorded annual product cost is $310,000, but supported replacement purchasing for the same modeled volume is $355,000. The earnings model would need to address a $45,000 recurring cost difference before any other changes. These are invented figures, not typical med spa costs or proof of wrongdoing.

Review rebates and credits separately. Determine whether they were earned, recorded in the correct period, tied to minimum volume, or specific to the seller. A buyer may not inherit the same terms. Keep uncertain savings out of the supported historical earnings case until their basis is established.

How should you describe improvements and historical issues to buyers?

Work with counsel on material disclosure and the appropriate audience. Explain the review scope, periods, findings, changes, and unresolved questions accurately. Do not market the practice as fully remediated unless qualified advisors support that conclusion within a clearly defined scope.

A new supplier policy may improve future operations while leaving past questions open. Keep these categories separate in the issue log. The buyer may need independent review, contractual protections, a reserve, a changed closing date, or a decision not to proceed.

Avoid claiming that a lower purchase price cures patient-safety or professional obligations. Some findings affect whether and how services can continue, not merely what the business is worth. The final operating plan must reflect the actual products, professionals, controls, and evidence that remain after closing.

Which controls should be ready for the handover?

Assign purchasing authority, approved supplier verification, invoice retention, receiving checks, inventory reconciliation, exception escalation, and review responsibilities. Tailor the controls to the actual services and applicable requirements. Staff should know when to stop an ordinary purchasing workflow and involve the responsible professional.

1. Preserve original supplier and inventory evidence.
2. Verify the source and product categories.
3. Reconcile financial and physical records.
4. Escalate questionable findings to qualified reviewers.
5. Document changes and remaining historical exposure.
6. Transfer a usable purchasing and exception process.

Use the seller hub, injectables economics guide, diligence guide, and 90-Day Pre-Sale Sprint to place sourcing work in the sale plan. A credible seller presents traceable evidence and candid limits rather than asking buyers to trust a margin percentage.

Maintain an exception register after the initial cleanup. Record missing invoices, supplier-status changes, mismatched deliveries, unexplained inventory adjustments, and the documented resolution. Give the buyer the current process and appropriate historical records at handover. A one-time folder cleanup is less valuable than an operating system that detects the next problem, assigns responsibility, and preserves the evidence needed to respond without rewriting the past.

Ask the transaction team to identify what evidence supports closing readiness and what remains outside its review. A purchasing reconciliation may support the financial schedule without authenticating every item. A new supplier approval may support future orders without resolving a past complaint. Keeping those conclusions separate prevents one useful piece of work from being promoted into a broader clearance that nobody actually provided. The final issue register should state who reviewed each matter and the scope of that review.

Educational analysis prepared with AI-assisted research for The Med Spa Broker. “Last reviewed” records the source and editorial check date; it does not imply review by an attorney, clinician, or independent appraiser. Read our editorial standards.